Literature DB >> 8732209

Paraproteinaemic neuropathies.

G C Miescher1, A J Steck.   

Abstract

Paraproteinaemia and neuropathy are each relatively frequent and may be associated by chance. However, a number of significant relationships have to be ruled out in the differential diagnosis. Malignant gammopathy should be excluded: multiple myeloma can lead to compression of the spinal cord or cauda equina; primary amyloidosis is occasionally involved; the rare but intriguing POEMS syndrome, consisting of polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes, usually accompanies osteosclerotic myeloma. It can be associated with angio-follicular lymph node hyperplasia and needs to be recognized because radioablative therapy is curative. The 'benign' monoclonal gammopathies of undetermined significance, known as MGUS, are much more frequent. There is an IgM MGUS group with predominantly distal sensorimotor demyelinating polyneuropathy and another rather heterogeneous group with IgG or IgA MGUS and a tendency to a favourable response to plasmapheresis. The role of the monoclonal IgG and IgA antibodies is unclear. This chapter has focused on the pathogenetic mechanisms of neuropathies associated with IgM MGUS. In the majority of cases, monoclonal autoantibodies specific for particular carbohydrate epitopes bind to myelin and are now recognized as the primary cause of the disease manifestations, including widening of the myelin lamellae. While the autoantibodies have been shown to bind complement, the presence of inhibitors is invoked to explain the absence of acute inflammatory changes. The epitopes recognized with the highest affinity by the auto-antibodies are present on the myelin-associated glycoprotein (MAG) and could interfere with cell adhesion and cellular signally processes. In addition, binding to antigenically similar glycoproteins, such as PO, PMP-22 and some acidic glycolipids, may be a contributory factor. It is generally accepted that the anti-MAG autoantibodies are inducing a progressive demyelinating polyneuropathy by modifying axon-Schwann cell interactions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8732209

Source DB:  PubMed          Journal:  Baillieres Clin Neurol        ISSN: 0961-0421


  4 in total

1.  Connecting impairment, disability, and handicap in immune mediated polyneuropathies.

Authors:  I S J Merkies; P I M Schmitz; F G A van der Meché; J P A Samijn; P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

Review 2.  The role of glycoproteins in neural development function, and disease.

Authors:  K C Breen; C M Coughlan; F D Hayes
Journal:  Mol Neurobiol       Date:  1998-04       Impact factor: 5.590

3.  Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies.

Authors:  I S J Merkies; P I M Schmitz; F G A van der Meché; J P A Samijn; P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-05       Impact factor: 10.154

4.  Modifying the Medical Research Council grading system through Rasch analyses.

Authors:  Els Karla Vanhoutte; Catharina Gerritdina Faber; Sonja Ingrid van Nes; Bart Casper Jacobs; Pieter Antoon van Doorn; Rinske van Koningsveld; David Reid Cornblath; Anneke Jelly van der Kooi; Elisabeth Aviva Cats; Leonard Hendrik van den Berg; Nicolette Claudia Notermans; Willem Lodewijk van der Pol; Mieke Catharina Elisabeth Hermans; Nadine Anna Maria Elisabeth van der Beek; Kenneth Craig Gorson; Marijke Eurelings; Jeroen Engelsman; Hendrik Boot; Ronaldus Jacobus Meijer; Giuseppe Lauria; Alan Tennant; Ingemar Sergio José Merkies
Journal:  Brain       Date:  2011-12-20       Impact factor: 13.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.